Paper326117
Cis-diamminedichloroplatinum (II). A new anticancer drug.
Rozencweig M and 3 others. Ann Intern Med, 1977. Cited by 513 papers, by iCite.
Cite this record
ConductScience Library. Cis-diamminedichloroplatinum (II). A new anticancer drug. Papers, record 326117. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/326117
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cisplatin | Major topic |
| Neoplasms | Major topic |
| Child | |
| Colonic Neoplasms | |
| Female | |
| Head and Neck Neoplasms | |
| Hearing Disorders | |
| Humans | |
| Kidney Diseases | |
| Male | |
| Nausea | |
| Ovarian Neoplasms | |
| Testicular Neoplasms | |
| Urinary Bladder Neoplasms | |
| Vomiting |
Source PubMed
Cited by80
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 513 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41562768 | Cisplatin as a Xenobiotic Agent: Molecular Mechanisms of Actions and Clinical Applications in Oncology. | J Xenobiot | 2026 | https://conductscience.org/library/papers/41562768 | PubMed |
| 40956032 | Metabolic Reprogramming of Cancer Cells and Therapeutics Targeting Cancer Metabolism. | Cancer Med | 2025 | https://conductscience.org/library/papers/40956032 | PubMed |
| 40649349 | Synthesis, Structure, Electrochemistry, and In Vitro Anticancer and Anti-Migratory Activities of (Z)- and (E)-2-Substituted-3-Ferrocene-Acrylonitrile Hybrids and Their Derivatives. | Molecules | 2025 | https://conductscience.org/library/papers/40649349 | PubMed |
| 39905500 | Intratympanic N-acetylcysteine in the prevention of cisplatin-induced ototoxicity: a systematic review and meta-analysis of randomized controlled trials. | BMC Pharmacol Toxicol | 2025 | https://conductscience.org/library/papers/39905500 | PubMed |
| 38885368 | Anti-Quenching NIR-II Excitation Phenylboronic Acid Modified Conjugated Polyelectrolyte for Intracellular Peroxynitrite-Enhanced Chemo-Photothermal Therapy. | Adv Sci (Weinh) | 2024 | https://conductscience.org/library/papers/38885368 | PubMed |
| 38424294 | Pharmacodynamics and biodistribution of [195mPt]cisplatin(CISSPECT®) in head and neck squamous cell carcinoma. | EJNMMI Res | 2024 | https://conductscience.org/library/papers/38424294 | PubMed |
| 36618350 | Targeting cancer-specific metabolic pathways for developing novel cancer therapeutics. | Front Immunol | 2022 | https://conductscience.org/library/papers/36618350 | PubMed |
| 36615466 | Highlights of New Strategies to Increase the Efficacy of Transition Metal Complexes for Cancer Treatments. | Molecules | 2022 | https://conductscience.org/library/papers/36615466 | PubMed |
| 35829930 | Property evaluation of two anticancer candidate platinum complexes with N-isobutyl glycine ligand against human colon cancer. | Biometals | 2022 | https://conductscience.org/library/papers/35829930 | PubMed |
| 35632435 | Renal Function Outcomes in Metastatic Non-Small-Cell Lung Carcinoma Patients Treated with Chemotherapy or Immune Checkpoint Inhibitors: An Unexpected Scenario. | Vaccines (Basel) | 2022 | https://conductscience.org/library/papers/35632435 | PubMed |
| 35528662 | The role of hollow magnetic nanoparticles in drug delivery. | RSC Adv | 2019 | https://conductscience.org/library/papers/35528662 | PubMed |
| 35477416 | Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy. | J Hematol Oncol | 2022 | https://conductscience.org/library/papers/35477416 | PubMed |
| 33761993 | The combination of G-CSF and AMD3100 mobilizes bone marrow-derived stem cells to protect against cisplatin-induced acute kidney injury in mice. | Stem Cell Res Ther | 2021 | https://conductscience.org/library/papers/33761993 | PubMed |
| 32708025 | Phosphorus Dendrimers as Nanotools against Cancers. | Molecules | 2020 | https://conductscience.org/library/papers/32708025 | PubMed |
| 30682873 | Oxaliplatin-Based Intra-arterial Chemotherapy in Colo-Rectal Cancer Liver Metastases: A Review from Pharmacology to Clinical Application. | Cancers (Basel) | 2019 | https://conductscience.org/library/papers/30682873 | PubMed |
| 27721894 | The Fruit Hull of Gleditsia sinensis Enhances the Anti-Tumor Effect of cis-Diammine Dichloridoplatinum II (Cisplatin). | Evid Based Complement Alternat Med | 2016 | https://conductscience.org/library/papers/27721894 | PubMed |
| 25982100 | Insights into the structure-activity relationships of chiral 1,2-diaminophenylalkane platinum(II) anticancer derivatives. | J Biol Inorg Chem | 2015 | https://conductscience.org/library/papers/25982100 | PubMed |
| 25020203 | Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection. | PLoS One | 2014 | https://conductscience.org/library/papers/25020203 | PubMed |
| 24283498 | Synthetic methods for the preparation of platinum anticancer complexes. | Chem Rev | 2014 | https://conductscience.org/library/papers/24283498 | PubMed |
| 23122180 | Ototoxicity in dogs and cats. | Vet Clin North Am Small Anim Pract | 2012 | https://conductscience.org/library/papers/23122180 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/326117
GET https://conductscience.org/api/papers/v1/326117/cited_by?page=2